Formosa Laboratories, Inc.
Raising the Standards of Quality and Compliance

Located in Taiwan’s renowned Taoyuan City, Formosa Laboratories serves as a market-leading CDMO with a global reach. The company’s phenomenal entry into the CDMO space was facilitated by its founder Dr. C. Y. Cheng, in 1995. His background in medicinal chemistry, along with extensive expertise in the active pharmaceutical ingredient (API) field, enabled him to discern the challenges in the industry and pivot Formosa’s portfolio accordingly. After that, it did not take long for the company to gain the approval of the U.S. FDA and several other regulatory authorities, which cleared its path into the global pharmaceutical market.Today, Formosa serves as the backbone for many large pharmaceutical clients. Its robust CDMO services range from the development of APIs and antibody drug conjugates (ADCs)to the production of cytotoxic and non-cytotoxic injectables. To add to that, the company is fast becoming a go-to service provider for aseptic liquid filling and lyophilisation.

Formosa’s streamlined and cost-effective CDMO services are proving vital for pharma clients seeking to produce and deploy life-saving drugs into the market. Their entire drug commercialisation cycle is enhanced by superior procurement and project management capabilities to ensure even the tightest deadlines are met on time. As a result, Formosa’s clients can focus on maintaining their market presence or commencing new market entries without having to worry about the drug manufacturing operations or the quality of their end products.

A Cutting-Edge Facility for Optimised Results

Formosa’s high standing in the CDMO space can be attributed to its state-of-the-art facility, which supports its clients from the clinical stage to the commercialisation of their pharmaceutical products. While a pilot (pre-commercial) scale production line in the facility is competent to produce small test volumes of APIs, ADCs, and injectable products, clients seeking large-scale production can always depend on Formosa’s high-speed commercial manufacturing line.

Formosa’s streamlined and cost-effective CDMO services are proving vital for pharma clients seeking to produce and deploy life-saving drugs into the market

Moreover, because of regularvaporised hydrogen peroxide (VHP) decontamination, the injectable facility is a safe and secure destination for the production of biologic drugs. And as an added advantage, the facility follows full cGMP specifications, ensuring seamless compliance with regulations, helping pharma clients with quicker entry into new markets.

A testament to Formosa’s capabilities is its recent collaboration with a European client. Formosa not only helped the company to file an investigational drug application (IDA) but also successfully develop a complex ADC. Thanks to its robust facility and skilled workforce, Formosa quickly transitioned the project from the development stage to production, thus paving the way for the commercialisation of the drug. Since then, Formosa—together with its sister company, EirGenix Biotech—has supported several other clients with their abbreviated new drug application (ANDA) and new drug application (NDA) filing.

The Gateway to Sustainable Commercialisation

Propelled by its successful collaborations, Formosa is witnessing significant growth in the pharmaceutical space. It has even been rated as an established API manufacturer by Clarivate Analytics—a provider of trusted information and insights. The company’s position of excellence today is being facilitated by Formosa’s tight-knit team, which embodies the company’s motto: “Hope, Enthusiasm, Innovation, and Sustainability.”Thus, backed by this work culture, Formosa is boosting efficiency, confidentiality, and productivity to benefit its customers and business partners. The Formosa team also takes a special interest in ensuring sustainable drug production and eliminating negative impacts on the environment.

Even today, amid the opposing currents of the pandemic, Formosa is striding ahead with discipline and focus. Especially, its project management strategies facilitate seamless coordination among the various departments as well as partners, ensuring a smooth workflow. Formosa is also taking measures to streamline the production schedule amid global lockdowns through advanced planning in the supply chain management of raw materials.

Having carved a niche for itself in the CDMO field, Formosa will continue to maintain its position as a major supplier of APIs to life-saving drug companies around the world. The company also expects to become a major provider of fill/finish service for antibody and other protein drugs. In the upcoming years, Formosa will keep on innovating and enhancing its capabilities to meet the evolving requirements of the global pharma industry.